Polycystic ovarian syndrome: long-term surgical outcomes (literature review)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Polycystic ovarian syndrome (PCOS) is a fairly common disease that occupies one of the leading positions among the reasons of endocrine infertility. Women with this diagnosis have an increased risk of developing diabetes mellitus, cardiovascular disease, metabolic syndrome (dyslipidemia, decreased sensitivity to peripheral tissue insulin, hyperinsulinemia). Currently, a step-by-step and individual approach to treatment has been applied, including both conservative treatments and surgical ones.

Full Text

Restricted Access

About the authors

Tat'yana S. Gracheva

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: gracheva_91@mail.ru
ORCID iD: 0000-0001-5102-5310

graduate student

Russian Federation, Moscow

Elena A. Sosnova

I.M. Sechenov First Moscow State Medical University

Email: gracheva_91@mail.ru
ORCID iD: 0000-0001-5102-5310

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow


  1. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–2438.
  2. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749.
  3. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011.
  4. March WA, Moore VM., Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551.
  5. Moran C, Tena G, Moran S, et al. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest. 2010;69:274–280.
  6. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067–3073.
  7. Azziz R. Polycystic ovary syndrome, reproductive endocrinology and infertility. Obstet Gynecol. 2018;132(2):321–336. doi: 10.1097/AOG.0000000000002698
  8. Chernukha GE. Modern concepts of polycystic ovary syndrome. Consilium Medicum. 2002;4(10 suppl.):16–19. (In Russ).
  9. Fauser BC, Tarlatzis BC, Rebar RW, et al.; Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38. е25. doi: 10.1016/j.fertnstert.2011.09.024
  10. Chandrasekaran S, Sagili H. Metabolic syndrome in women with polycystic ovary syndrome. The Obstetrician & Gynaecologist. 2018;20(4):245–252. doi: 10.1111/tog.12519
  11. Guzick DS. Polycystic Ovary Syndrome. Obstet Ginecol. 2004;103(1):181–193. doi: 10.1097/01.AOG.0000104485.44999.C6
  12. Dedov II, Butrova SA. Polycystic ovary syndrome and metabolic syndrome. Ozhirenie i metabolizm. 2006;(1):30–40. (In Russ).
  13. Micola M, Hiilesmaa V, Halttunen M, Shonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16(2):226–229. doi: 10.1093/humrep/16.2.226
  14. Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight, hyperinsulinaemia, and gonadotropin levels in the polycystic ovary syndrome: evidence of two distinct populations. Fertil Steril. 1992;58:487–491.
  15. Grulet H, Hecart AC, Delemer B, et al. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin Endocrinol. (Oxf.) 1993;38:621–626.
  16. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotropins and sex steroids in premenopausal woman. Clin Endocrinol. (Oxf.) 1994;41:473–481.
  17. Jacobs HS. Polycystic ovary syndrome: aetiology and management. Curr Opin Obstet Gynecol. 1995;7:203–208.
  18. Morales AJ, Laughlin GA, Butzow T, et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996;81:2854–2864.
  19. Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994;79:1686–1692.
  20. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome. N Engl J Med. 1996;335:617–623. doi: 10.1056/NEJM199608293350902
  21. Tikhomirov AL, Lubnin DM. Polycystic ovary syndrome: facts, theories, hypotheses. Mezhdunarodnyi endokrinologicheskii zhurnal. 2007;5(11):6–8. (In Russ).
  22. Manusharova RA, Cherkezova EI. Modern approaches to the treatment of polycystic ovaries. In: Sbornik tezisov dokladov XI Rossiiskogo natsional’nogo kongressa «Chelovek i lekarstvo». 2002 Аpr 19–23; Моscow, Russian Federation. Moscow; 2004. P: 243. (In Russ).
  23. Kim LH, Taylor AE, Barbieri RL. Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility? Fertil Steril. 2000;73(6):1097–1098.
  24. Grishchenko VI, Kozub NI. Endoscopy in the diagnosis and treatment of female infertility. Khar’kov: Osnova; 1998. 216 p. (In Russ).
  25. Pishchulin AA, Karpova EA. Ovarian hyperandrogenism and metabolic syndrome. Russkii meditsinskii zhurnal. 2001;(2):93. (In Russ).

Copyright (c) 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies